CR Bard to market CorMedica's heart laser system:
This article was originally published in Clinica
CR Bard is to have exclusive, worldwide distribution rights to CorMedica's systems for catheter-based, percutaneous transluminal endomyocardial revascularisation (PTER) procedures. The products treat serious coronary artery disease by delivering laser energy through a catheter to create channels in the heart muscle. CorMedica is a privately-held company based in Natick, Massachusetts.
You may also be interested in...
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.
As interest in immune/inflammatory disease increases and savings achieved dip, payer focus on patient-reported outcomes for contracts reflects shift in focus, Avalere survey suggests.
After an eleventh-hour win last year that saw Congress repeal the medical device excise tax, AdvaMed is going more global. CEO Scott Whitaker sat down with Medtech Insight for a lengthy chat about what the lobby group will focus on in 2020, including reimbursement challenges, the upcoming medical device user-fee negotiations, and negotiations with governments that are key to the industry ecosystem.